Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892941 | 1.00 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL953015 | 0.98 | FKBP1A (0.48) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5980951 | 0.98 | FKBP1A (0.48) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL4202767 | 0.83 | FKBP1A (0.44) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL2731647 | 0.83 | FKBP1A (0.44) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL11490824 | 0.81 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13601738 | 0.81 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL11490823 | 0.81 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL4893219 | 0.81 | RAB9A (0.55) | ALDH1A1MAPTKDM4ETSHRHTT | |
| SCHEMBL5065864 | 0.80 | CHRM2 (0.43) | FKBP1AMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | claimed |
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | US | claimed |
| US-7125845-B2 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | claimed |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005010029-A1 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | claimed |
| EP-0656026-B1 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE | UNIV RUTGERS (US) | 1999-11-17 | — | — | EP | claimed |
| EP-0656026-A4 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE. | UNIV RUTGERS (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0656026-A1 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE | RUTGERS, THE STATE UNIVERSITY (US) | 1995-06-07 | — | — | EP | claimed |
| WO-1994004593-A1 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1994-03-03 | — | — | WO | claimed |
| US-5216115-A | Molded articles and drug delivery systems | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1993-06-01 | — | — | US | claimed |
| CN-106946867-B | FXR receptor modulators and its preparation method and application | 广州市恒诺康医药科技有限公司 | 2019-11-12 | — | — | CN | disclosed |
| US-7485662-B2 | Therapeutic agent for diabetes mellitus | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-20070167512-A1 | Lipid metabolism improving agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20060173066-A1 | Remedy for diabetes | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-0656026-A1 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE | RUTGERS, THE STATE UNIVERSITY (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5405847-A | Antiallergic, antiasthmatic, anxiolytic, hypotensive agents | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |
| US-5317077-A | Polyarylates containing derivatives of the natural amino acid l-tyrosine | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1994-05-31 | — | — | US | disclosed |
| WO-1994004593-A1 | POLYARYLATES CONTAINING DERIVATIVES OF THE NATURAL AMINO ACID L-TYROSINE | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5216115-A | Molded articles and drug delivery systems | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021330-A1 | Aza-peptide macrocyclic hepatitis c serine protease inhibitors | VIP, CTSC, DPP4 | FKBP1A 434/4885ALDH1A1 2329/4885MAPT 4684/4885 |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | VIP, CTSC, PRSS1 | FKBP1A 407/4885ALDH1A1 2265/4885MAPT 4748/4885 |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | FKBP1A 253/4885ALDH1A1 1543/4885MAPT 3804/4885 |
| US-20070167512-A1 | Lipid metabolism improving agent | LIPC, LIPA, FABP1 | FKBP1A 3538/4885ALDH1A1 282/4885MAPT 3382/4885 |
| US-20060173066-A1 | Remedy for diabetes | IAPP, GPR119, SLC5A1 | FKBP1A 1548/4885ALDH1A1 300/4885MAPT 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.